View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
June 1, 2018

Dicernas doses first patient in Group B portion of PHYOX trial

Dicerna Pharmaceuticals has dosed the first patient in the Group B portion of the PHYOX trial, a Phase l clinical study of DCR-PHXC for the treatment of primary hyperoxaluria (PH).

Dicerna Pharmaceuticals has dosed the first patient in the Group B portion of the PHYOX trial, a Phase l clinical study of DCR-PHXC for the treatment of primary hyperoxaluria (PH).

The single-ascending dose trial comprises two groups, A and B.

Group A is a placebo-controlled, single-blind, single-centre trial, which has enrolled 25 healthy subjects.

Group B, which is an open-label, multi-centre trial plans to enrol up to 16 patients with PH type 1 (PH1) and PH type 2 (PH2).

PHYOX’s primary objective is to investigate the safety and tolerability of single doses of DCR-PHXC in both the groups.

Its secondary objectives are the evaluation of the pharmacodynamic effect of single doses of DCR-PHXC on biochemical markers, as well as changes in urine oxalate concentrations, and characterisation of the pharmacokinetics of single doses of DCR-PHXC in healthy subjects and PH patients.

“The advancement of DCR-PHXC demonstrates our commitment to progressing novel science that has the potential to make a meaningful difference for this underserved patient population.”

Clinical proof-of-concept data from the PHYOX trial is expected to be available in the second half of this year.

Dicerna has already completed the Group A portion of the trial and has reported topline results from that portion.

Dicerna Pharmaceuticals chief medical officer Ralf Rosskamp said: “While the PHYOX study remains blinded to treatment assignment, the early safety and tolerability data from healthy volunteers in Group A are encouraging.

“The advancement of DCR-PHXC demonstrates our commitment to progressing novel science that has the potential to make a meaningful difference for this underserved patient population.”

DCR-PHXC is an investigational drug in development for the treatment of all forms of PH, a type of severe, rare, genetic liver disorders caused by overproduction of oxalate, a natural chemical in the body that is normally removed as waste through the kidneys.

The drug has recently received orphan drug designation from the US Food and Drug Administration (FDA).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU